Lung Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Aged >= 18 years and 70%); (5) Performance status of ECOG 0 or 1; (6) Preoperative ASA scoring (American society of anesthesiology) class I to III; (7) Patients can cooperate with treatment and research, and can also fully understand the contents of informed consent and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Preoperative CT scan or pathological biopsy indicated the presence of mediastinal lymph node metastasis; (2) Evidence indicated that there is distant metastasis or pleural metastasis found during operation; (3) Patients with other malignant tumors; (4) Patients who have undergone neoadjuvant chemoradiotherapy, or received radiotherapy and (or) chemotherapy because of the history of malignant tumors; (5) Patients with a history of chest trauma or chest surgery; (6) Female during pregnancy or lactation; (7) Patients with severe damage to heart, liver and kidney function (grade 3~4, ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FEV1 at the 12th months postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative length of stay;The indwelling time of postoperative closed thoracic drainage tube;Lung function indicators at the 1st, 3rd, 6th and 12th months postoperatively: FEV1, FVC, and DLCO;Lung morphology evaluation at the 1st, 3rd, 6th and 12th months postoperatively (CT reconstruction and imageological assessment);Postoperative life quality scale scores (SF-36 and SGRQ) at the 1st, 3rd, 6th, 12th and 24th months post-operatively after surgery;The incidence rate of postoperative complications; | — |
Countries
China
Contacts
Shanghai Pulmonary Hospital